ArticleJournal of atherosclerosis and thrombosis2019
Circulating Sulfatide, A Novel Biomarker for ST-Segment Elevation Myocardial Infarction.
Article in Journal of atherosclerosis and thrombosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Fecal sulfatide as a non-invasive biomarker for predicting coronary heart disease.European journal of medical research · 2025Article
- Predictive value of fecal sulfatide and neutrophil-to‑lymphocyte ratio in coronary heart disease.Experimental and therapeutic medicine · 2025Article
- Construction and optimization of multi-platform precision pathways for precision medicine.Scientific reports · 2024Article
- MiR-206 may regulate mitochondrial ROS contribute to the progression of Myocardial infarction via TREM1.BMC cardiovascular disorders · 2023Article
- Relationship of Sulfatides Physiological Function and Peroxisome Proliferator-Activated Receptor α.Neurochemical research · 2023Review
- Lipidomics Profiling and Risk of Coronary Artery Disease in the BioHEART-CT Discovery Cohort.Biomolecules · 2023Article
- Serum sulfatide level is associated with severe systemic vasculitis with kidney involvement.Frontiers in immunology · 2023Article
- Review article: vascular effects of PPARs in the context of NASH.Alimentary pharmacology & therapeutics · 2022Review
- Serum Sulfatide Levels as a Biomarker of Active Glomerular Lesion in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Pilot Study.Journal of clinical medicine · 2022Article
- Effects of hypertension and antihypertensive treatments on sulfatide levels in serum and its metabolism.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsST-segment elevation myocardial infarction (STEMI) is an acute inflammatory and thrombotic disease due to coronary artery atherosclerotic lesions. Studies have established the correlation of serum sulfatides with inflammation, thrombogenesis, and atherosclerosis. We observed that serum sulfatides level significantly increased in STEMI patients. In this study, we try to identify the relationship of serum sulfatides level on clinical outcomes of patients in STEMI.
methodsSerum sulfatides level was monitored in 370 inpatients within 24 h of STEMI onset. On the basis of the level of serum sulfatides that was below 10 µmol/L in the normal population, the patients were divided into two groups with the median value of 15.2 µmol/L; low sulfatide group [serum sulfatides level ≤ 15.2 µmol/L (n=200)] and high sulfatide group [serum sulfatides level ＞ 15.2 µmol/L (n=170)]. Patients' baseline characteristics, in-hospital outcomes, and late major adverse cardiovascular events (MACE) were analyzed. Independent incident for in-hospital death and late adverse events were modeled by multivariate logistic and Cox regression analysis.
resultsBetween the two groups, there were no differences in the angiographic characteristics, percutaneous coronary intervention (PCI) results, and in-hospital recovery. However, high serum sulfatides level is positively correlated with increased rate of in-hospital death (OR 0.971; 95% CI 0.926-0.990, p=0.019). In addition, this group of patients has more cumulative incidences of target vessel revascularization (TVR) (23% vs. 8%, p＜0.05) and increased overall MACE (28% vs. 10%, p ＜0.05). Cox regression analysis indicated that high serum sulfatides level contributes to TVR and overall MACE.
conclusionsElevated serum sulfatides level positively correlate with in-hospital death and complications (TVR and MACE) in STEMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.